Uncategorized

New Research Shows How Psychedelics Expand and Amplify Sections of the Brain

If you do some research about what people experience when they consume “magic mushrooms” and other psychedelics, you will come across expressions along the lines of “going on a trip.” The psychedelic experience users have has to do with how the substances affect the regions of the brain associated with dreaming, and now scientists have done research showing how this happens.

The study, which was published in the journal Human Brain Mapping, relied on volunteers who were injected with psilocybin (a psychedelic chemical found in magic mushrooms). The brains of these study subjects were then scanned to analyze the regions that displayed heightened or muted levels of activation. These study subjects were compared to a control group that didn’t receive the psilocybin injections.

The researchers made two key discoveries. First, the brain scans showed that the study subjects who got psilocybin injections displayed a higher amplitude or volume of activity in the parts of the brain which are consistently activated while one is in a dream state. These regions are associated with the ancient emotion system of the brain.

Secondly, the researchers established that the psychedelic chemical made the study subjects to experience expanded levels of consciousness. This means that those individuals had a wider capacity to form associations in the brain once the psychedelic compound became active in their bloodstream.

These findings make sense out of the anecdotal reports from users of psychedelics who invariably described their experience as one in which they felt a deep connection with everything around them, a sort of transformation that triggered a diminishing of the sense of self in favor of oneness.

The implications of this research shed more light on the potential uses of psychedelics as therapeutic products. For example, a lot of people who are battling a life-threatening medical condition, such as end-stage cancer, tend to feel that life is meaningless and that their life should come to a speedy end. That despondence and hopelessness isn’t just hard on the patients themselves but also on their families, caregivers and the healthcare teams doing their best in the circumstances.

Could psychedelics administered under strict medical supervision help such patients get to a better mental state? The expanded level of consciousness mapped by the researchers seems to suggest that this could be the case since the patient could feel a deep connection with the people and things around them to the extent that they would value every waking moment right to the very end.

Analysts say such exciting possibilities may be the motivation behind the massive investments being made in psychedelics research and development by companies like Psybio Therapeutics, Inc.

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a far-out information destination focused on (1) delivering the freshest headlines on psychedelics and ‘shrooms, (2) issuing PsychedelicNewsBreaks that are specially crafted to keep the grooviest investors in-the-know, (3) laying down the choicest enhancements for corporate news releases, (4) doing our public and private client-partners a solid with full-service distribution and social media services and (5) taking custom-built corporate communication solutions to the max. PNW has a totally awesome spot in the booming psychedelics space, and our ace team of journalists is always grinding to help our growing roster of clients reach a sizable audience of investors, consumers and media outlets. We’ve got a network of more than 5,000 key syndication outlets to help you deliver dy-no-mite visibility, recognition and content within the psychedelic industry. PsychedelicNewsWire (PNW) is where PSYCHEDELIC news, content and information converge.

To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit https://www.psychedelicnewswire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Chris@PNW

Share
Published by
Chris@PNW

Recent Posts

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Files Abbreviated New Drug Application for Preservative-Free IV Ketamine NRX-100 Amid Ongoing Shortage

The company targets all current ketamine indications, including anesthesia and pain management. The U.S. is…

4 days ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Signs Agreement to Acquire Kadima to Launch $100M Psychiatry Clinic Network

The Kadima Neuropsychiatry Institute acquisition is part of NRx subsidiary HOPE Therapeutics’ model for a…

2 weeks ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Announces $10.3 Million Financing to Expand HOPE Clinic Network, Advances FDA Drug Approval

Subsidiary HOPE Therapeutics signed a $7.8 million debt financing term sheet with Universal Capital. Combined…

3 weeks ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Subsidiary, HOPE Therapeutics, to Expand Interventional Psychiatry Treatment with Kadima Institute Acquisition

Kadima Neuropsychiatry Institute is expected to become the clinical model for HOPE Therapeutics’ nationwide network…

3 weeks ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Is ‘One to Watch’

NRx Pharmaceuticals is advancing a pipeline of innovative therapies targeting multibillion-dollar unmet needs in central…

4 weeks ago

Republican Lawmakers Embrace Psychedelic Therapies in Shift Toward Veteran Mental Health Reform

Rep. Morgan Luttrell (R-Texas), a retired Navy SEAL, is part of a rising wave of…

4 weeks ago